Company: HURA
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0001193125-25-137135
Chunk: 1

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 8-K
Item: Item 1.01
Chunk 1
---
 $10.38 million in gross proceeds from the additional closings above, provided that the conditions to funding are satisfied. The Company currently plans to use the net proceeds from the Offering for cash requirements for the closing of the proposed merger with Kineta, Inc., to fund the initiation of the Phase 3 Trial for IFx-2.0, to fund the advancement of KVA12123 to a Phase 2 trial and for other working capital needs.

The Warrants have an exercise price per share equal to $3.3125 and will expire on the fifth (5th) anniversary of the later of (i) December 3, 2025 and (ii) the date of the implementation of the Authorized Share Increase Proposal in the Company’s Form S-4Registration Statement relating to the Kineta Merger. The exercise price of the Warrants is subject to proportional adjustment for stock splits, reverse stock splits, and similar transactions.

The Shares, Warrants and the shares of Common Stock issuable upon exercise of the Warrants were issued in a private placement and have not been registered under the Securities Act of 1933, as amended (the “ Securities Act”), and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder.

The Company has agreed to file a registration statement to register the resale of the Shares and shares of Common Stock underlying the Warrants no later than 60 calendar days following the date of the Initial Closing and to use reasonable efforts to cause such registration statement to become effective within 120 calendar days following the date of the Initial Closing.

In connection with the Offering, the Company engaged Paulson Investment Company, LLC as exclusive placement agent, and Brookline Capital Markets, a division of Arcadia Securities, provided equity market advisory services to the Company.

***

The foregoing summaries of the Securities Purchase Agreement and the Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, copies of which are attached hereto as Exhibits 10.1 and 4.1, respectively, and are each incorporated herein by reference. The representations, warranties and covenants made by the Company in any agreement that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements. In addition, the assertions embodied in any representations, warranties and coven